Wed, 08/14/2013 - 12:00pm
The first clinical trial of revolutionary stem cells that won a Nobel Prize for their developer has been greenlit.
The cells, called induced pluripotent stem (iPS) Cells, will be morphed into retinal cells, then given to six patients with a major cause of blindness: age-related macular degeneration (AMD).
The trial, approved by Japan Health Minister Norihisa Tamura, will be led next summer by Masayo Takahashi. She is a retina regeneration expert, and a colleague of the man who first developed iPS cells: Shinya Yamanaka.
The trial epitomizes, to many, Japan’s determination to dominate the iPS cell field, an ambition that kicked into high gear when Yamanaka shared the Nobel Prize for Physiology or Medicine last October for his iPS cell work.
“If things continue this way, this will be the first in-clinic study in iPS cell technology,” says Doug Sipp of the Riken Center for Developmental Biology (CDB). The CDB, Takahashi’s institute, will co-run the trial with Kobe’s Institute for Biomedical Research and Innovation. "It's exciting."Read the whole article at Bio Science Technology